Cargando…

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey

OBJECTIVES: To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure. DESIGN: A national cross-sectional survey conducted in 2018 among phy...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoll, Marlene, Hubenschmid, Lara, Koch, Cora, Lieb, Klaus, Egloff, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234799/
https://www.ncbi.nlm.nih.gov/pubmed/35750457
http://dx.doi.org/10.1136/bmjopen-2021-055963
_version_ 1784736158342709248
author Stoll, Marlene
Hubenschmid, Lara
Koch, Cora
Lieb, Klaus
Egloff, Boris
author_facet Stoll, Marlene
Hubenschmid, Lara
Koch, Cora
Lieb, Klaus
Egloff, Boris
author_sort Stoll, Marlene
collection PubMed
description OBJECTIVES: To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure. DESIGN: A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation. SETTING: Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation. PARTICIPANTS: German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation. PRIMARY OUTCOMES: (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016. RESULTS: Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn(2015,2016) = 1.33 vs 1.00, r(b)=−0.17, p>0.01; content: Mdn(2015,2016) = 3.00 vs 3.00, r(b)=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure. CONCLUSIONS: While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures.
format Online
Article
Text
id pubmed-9234799
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92347992022-07-08 Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey Stoll, Marlene Hubenschmid, Lara Koch, Cora Lieb, Klaus Egloff, Boris BMJ Open Health Policy OBJECTIVES: To investigate German physicians’ attitudes towards and experiences with voluntary disclosure of payments by pharmaceutical companies in a public database and their impact on future decisions for or against disclosure. DESIGN: A national cross-sectional survey conducted in 2018 among physicians who voluntarily disclosed at least one payment in the German transparency regulation. SETTING: Retrospective paper-pencil questionnaire about attitudes towards and experiences with voluntary payment disclosures in the first (2015) and second (2016) years of the German transparency regulation. PARTICIPANTS: German physicians who disclosed either in the first year only, the second year only, or in both years of the transparency regulation. PRIMARY OUTCOMES: (1) The probability to disclose in 2016, predicted by physicians’ experience of reactions from others in 2015, descriptive norms and attitudes towards transparency; (2) Frequency and (3) Content of reactions from others in 2015 compared with 2016. RESULTS: Data of 234 respondents were analysed (n=42, 45 and 147 physicians who disclosed in 2015, 2016 or both years, respectively). The probability to disclose in 2016 was not predicted by perceived reactions, norms or attitudes towards transparency (p>0.01). Most participants reported not to have received any reactions by patients (190/234, 81%), colleagues (128/234, 55%) or the private environment (153/234, 65%). Neither frequency nor content of reactions differed between the first and second years (scale 1–5; frequency: Mdn(2015,2016) = 1.33 vs 1.00, r(b)=−0.17, p>0.01; content: Mdn(2015,2016) = 3.00 vs 3.00, r(b)=0.19, p>0.01). However, media reporting, fear of reputational damage and a feeling of being defamed were mentioned as reasons for non-disclosure. CONCLUSIONS: While confirmatory analyses did not provide significant results, descriptive analyses showed that participants who voluntarily disclose payments mainly do not experience any reactions towards their disclosures but report fears about losing their reputation due to disclosures. BMJ Publishing Group 2022-06-24 /pmc/articles/PMC9234799/ /pubmed/35750457 http://dx.doi.org/10.1136/bmjopen-2021-055963 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Policy
Stoll, Marlene
Hubenschmid, Lara
Koch, Cora
Lieb, Klaus
Egloff, Boris
Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_full Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_fullStr Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_full_unstemmed Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_short Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
title_sort physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234799/
https://www.ncbi.nlm.nih.gov/pubmed/35750457
http://dx.doi.org/10.1136/bmjopen-2021-055963
work_keys_str_mv AT stollmarlene physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT hubenschmidlara physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT kochcora physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT liebklaus physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey
AT egloffboris physiciansattitudestowardsdisclosureofpaymentsfrompharmaceuticalcompaniesinanationwidevoluntarytransparencydatabaseacrosssectionalsurvey